Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Yang, Sheng Li ^a   Fang, Xiefan ^b   Huang, Zao Zao ^a   Liu, Xiang Jie ^a   Xiong, Zhi Fan ^a   Liu, Ping ^a   Yao, Hong Yi ^a   Li, Chang Hai ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DNA POLYMORPHISM; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; EVALUATION STUDY; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; GLYPICANS; HUMANS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908286039     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/127831     Document Type: Review

References (41)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA Cancer Journal for Clinicians 2012 62 1 10 29 10.3322/caac.20138 2-s2.0-84855792427
2. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 2-s2.0-78049485263
3. Blechacz B., Mishra L., Hepatocellular carcinoma biology. Recent Results in Cancer Research 2013 190 1 20 10.1007/978-3-642-16037-0-1 2-s2.0-84868329935
4. European Association for the Study of the Liver, EASL clinical practice guidelines: management of cholestatic liver diseases. Journal of Hepatology 2009 51 2 237 267 10.1016/j.jhep.2009.04.009 2-s2.0-67649205149
5. Abu El Makarem M., An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepatitis Monthly 2012 12 10, article e6122
6. Jia H.-L., Ye Q.-H., Qin L.-X., Budhu A., Forgues M., Chen Y., Liu Y.-K., Sun H.-C., Wang L., Lu H.-Z., Shen F., Tang Z.-Y., Xin W. W., Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clinical Cancer Research 2007 13 4 1133 1139 10.1158/1078-0432.CCR-06-1025 2-s2.0-33947204625
7. Grozdanov P. N., Yovchev M. I., Dabeva M. D., The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Laboratory Investigation 2006 86 12 1272 1284 10.1038/labinvest.3700479 2-s2.0-33751222537
8. Honsová E., Lodererová A., Fraňková S., Oliverius M., Trunečka P., Glypican-3 immunostaining significantly improves histoloqical diagnosis of hepatocellular carcinoma. Casopis Lekaru Ceskych 2011 150 1 37 40 2-s2.0-79951472721
9. Kandil D., Leiman G., Allegretta M., Trotman W., Pantanowitz L., Goulart R., Evans M., Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer 2007 111 5 316 322 10.1002/cncr.22954 2-s2.0-38449095281
10. Yu J.-P., Xu X.-G., Ma R.-J., Qin S.-N., Wang C.-R., Wang X.-B., Li M., Li M.-S., Ma Q., Xu W.-W., Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma. Journal of Clinical Laboratory Analysis 2014 10.1002/jcla.21733 2-s2.0-84896691091
11. Lee H. J., Yeon J. E., Suh S. J., Lee S. J., Yoon E. L., Kang K., Yoo Y. J., Kim J. H., Seo Y. S., Yim H. J., Byun K. S., Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut and Liver 2014 8 2 177 185 10.5009/gnl.2014.8.2.177 2-s2.0-84897004411
12. Badr E. A. E., Korah T. E., Ghani A. A., El-Sayed S., Badr S., Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. Alexandria Journal of Medicine 2014 50 3 221 226 10.1016/j.ajme.2014.01.002
13. Li B., Liu H., Shang H. W., Li P., Li N., Ding H. G., Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. African Health Sciences 2013 13 3 703 709 10.4314/ahs.v13i3.26 2-s2.0-84883664221
14. Chen M., Li G., Yan J., Lu X., Cui J., Ni Z., Cheng W., Qian G., Zhang J., Tu H., Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clinica Chimica Acta 2013 423 105 111 10.1016/j.cca.2013.04.026 2-s2.0-84878190138
15. Abdelgawad I. A., Mossallam G. I., Radwan N. H., Elzawahry H. M., Elhifnawy N. M., Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pacific Journal of Cancer Prevention 2013 14 12 7345 7349 10.7314/APJCP.2013.14.12.7345 2-s2.0-84893376655
16. Gomaa A. H. O., Aboraia G., Attia H., Elezawy H., Nafie E., ElBaz S., The diagnostic value of peripheral blood glypican-3 in patients with hepatocellular carcinoma. World Journal of Medical Sciences 2012 7 2 105 112
17. Wang W., Zhao L.-J., Wang Y., Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomarkers 2012 11 1 29 39 10.3233/CBM-2012-0261 2-s2.0-84864432828
18. Qiao S.-S., Cui Z.-Q., Gong L., Han H., Chen P.-G., Guo L.-M., Yu X., Wei Y.-H., Ha S.-A., Kim J. W., Jin Z.-T., Li S., Peng J.-R., Leng X.-S., Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepato-Gastroenterology 2011 58 110-111 1718 1724 2-s2.0-83355163496
19. Abd El Moety H. A., Abd El Moety A. A., Rostom Y., El Sawy M., Glypican-3 amino terminal marker for early detection of HCC. Hepatology International 2011 5 1 435
20. Zhang Q., Xiao Q., Lin Z., Ying X., Li Z., Lin J.-M., Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clinical Biochemistry 2010 43 12 1003 1008 10.1016/j.clinbiochem.2010.04.074 2-s2.0-77954310523
21. Youssef M., El-Sharkawy S., Abbas N., Clinical utility of Glypican-3 in hepatocellular carcinoma. International Journal of Integrative Biology 2010 10 1 41 47
22. Liu H., Li P., Zhai Y., Qu C.-F., Zhang L.-J., Tan Y.-F., Li N., Ding H.-G., Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World Journal of Gastroenterology 2010 16 35 4410 4415 10.3748/wjg.v16.i35.4410 2-s2.0-77957558765
23. Tangkijvanich P., Chanmee T., Komtong S., Mahachai V., Wisedopas N., Pothacharoen P., Kongtawelert P., Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Journal of Gastroenterology and Hepatology 2010 25 1 129 137 10.1111/j.1440-1746.2009.05988.x 2-s2.0-73449108795
24. Beale G., Chattopadhyay D., Gray J., Stewart S., Hudson M., Day C., Trerotoli P., Giannelli G., Manas D., Reeves H., AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008 8, article 200 10.1186/1471-2407-8-200 2-s2.0-48549106668
25. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Research 2004 64 7 2418 2423 10.1158/0008-5472.CAN-03-2191 2-s2.0-11144357785
26. Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., Hosaka S., Beppu T., Ishiko T., Kamohara H., Ashihara H., Katagiri T., Furukawa Y., Fujiyama S., Ogawa M., Nakamura Y., Nishimura Y., Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochemical and Biophysical Research Communications 2003 306 1 16 25 10.1016/S0006-291X(03)00908-2 2-s2.0-0038054270
27. Capurro M., Wanless I. R., Sherman M., Deboer G., Shi W., Miyoshi E., Filmus J., Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003 125 1 89 97 10.1016/S0016-5085(03)00689-9 2-s2.0-0038786861
28. Wang Y., Yang H., Xu H., Lu X., Sang X., Zhong S., Huang J., Mao Y., Golgi protein 73, not Glypican-3, may be a tumor marker complementary to -Fetoprotein for hepatocellular carcinoma diagnosis. Journal of Gastroenterology and Hepatology 2014 29 3 597 602 10.1111/jgh.12461 2-s2.0-84897623755
29. Nault J.-C., Guyot E., Laguillier C., Chevret S., Ganne-Carrie N., N'Kontchou G., Beaugrand M., Seror O., Trinchet J.-C., Coelho J., Lasalle P., Charnaux N., Delehedde M., Sutton A., Nahon P., Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiology, Biomarkers & Prevention 2013 22 8 1343 1352 10.1158/1055-9965.EPI-13-0179 2-s2.0-84882275556
30. Özkan H., Erdal H., Koçak E., Tutkak H., Karaeren Z., Yakut M., Köklü S., Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. Journal of Clinical Laboratory Analysis 2011 25 5 350 353 10.1002/jcla.20484 2-s2.0-80052844270
31. Yasuda E., Kumada T., Toyoda H., Kaneoka Y., Maeda A., Okuda S., Yoshimi N., Kozawa O., Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatology Research 2010 40 5 477 485 10.1111/j.1872-034X.2010.00624.x 2-s2.0-77954381001
32. Higgins J. P. T., Thompson S. G., Deeks J. J., Altman D. G., Measuring inconsistency in meta-analyses. British Medical Journal 2003 327 7414 557 560 10.1136/bmj.327.7414.557 2-s2.0-0041876133
33. DerSimonian R., Laird N., Meta-analysis in clinical trials. Controlled Clinical Trials 1986 7 3 177 188 10.1016/0197-2456(86)90046-2 2-s2.0-0022992740
34. Deeks J. J., Macaskill P., Irwig L., The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology 2005 58 9 882 893 10.1016/j.jclinepi.2005.01.016 2-s2.0-23644432857
35. Altekruse S. F., Mcglynn K. A., Dickie L. A., Kleiner D. E., Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012 55 2 476 482 10.1002/hep.24710 2-s2.0-84856392791
36. Masuzaki R., Karp S. J., Omata M., New serum markers of hepatocellular carcinoma. Seminars in Oncology 2012 39 4 434 439 10.1053/j.seminoncol.2012.05.009 2-s2.0-84864438094
37. Ho M., Kim H., Glypican-3: a new target for cancer immunotherapy. European Journal of Cancer 2011 47 3 333 338 10.1016/j.ejca.2010.10.024 2-s2.0-79251599238
38. Tanaka M., Katayama F., Kato H., Tanaka H., Wang J., Qiao Y. L., Inoue M., Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. Journal of Epidemiology 2011 21 6 401 416 10.2188/jea.JE20100190 2-s2.0-84862942769
39. Huang T.-S., Shyu Y.-C., Turner R., Chen H.-Y., Chen P.-J., Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Systematic Reviews 2013 2 article 37 10.1186/2046-4053-2-37 2-s2.0-84886542321
40. Liu X.-F., Hu Z.-D., Liu X.-C., Cao Y., Ding C.-M., Hu C.-J., Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis. Clinical Biochemistry 2014 47 3 196 200 10.1016/j.clinbiochem.2013.12.007 2-s2.0-84893746921
41. Xu C., Yan Z., Zhou L., Wang Y., A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. Journal of Cancer Research and Clinical Oncology 2013 139 8 1417 1424 10.1007/s00432-013-1458-5 2-s2.0-84880920917